Literature DB >> 19966768

Memantine strikes the perfect balance.

Albert R La Spada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19966768     DOI： 10.1038/nm1209-1355

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  11 in total

1.  The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.

Authors:  A Beister; P Kraus; W Kuhn; M Dose; A Weindl; M Gerlach
Journal:  J Neural Transm Suppl       Date:  2004

2.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.

Authors:  Montserrat Arrasate; Siddhartha Mitra; Erik S Schweitzer; Mark R Segal; Steven Finkbeiner
Journal:  Nature       Date:  2004-10-14       Impact factor: 49.962

Review 3.  Mechanism of the eukaryotic chaperonin: protein folding in the chamber of secrets.

Authors:  Christoph Spiess; Anne S Meyer; Stefanie Reissmann; Judith Frydman
Journal:  Trends Cell Biol       Date:  2004-11       Impact factor: 20.808

Review 4.  Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.

Authors:  Stuart A Lipton
Journal:  Nat Rev Drug Discov       Date:  2006-02       Impact factor: 84.694

5.  Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.

Authors:  Libin Cui; Hyunkyung Jeong; Fran Borovecki; Christopher N Parkhurst; Naoko Tanese; Dimitri Krainc
Journal:  Cell       Date:  2006-10-06       Impact factor: 41.582

6.  Memantine in moderate-to-severe Alzheimer's disease.

Authors:  Barry Reisberg; Rachelle Doody; Albrecht Stöffler; Frederick Schmitt; Steven Ferris; Hans Jörg Möbius
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

7.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

8.  Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

Authors:  Jean-Marc Orgogozo; Anne-Sophie Rigaud; Albrecht Stöffler; Hans-Jorgen Möbius; Françoise Forette
Journal:  Stroke       Date:  2002-07       Impact factor: 7.914

9.  Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity.

Authors:  H S Chen; J W Pellegrini; S K Aggarwal; S Z Lei; S Warach; F E Jensen; S A Lipton
Journal:  J Neurosci       Date:  1992-11       Impact factor: 6.167

10.  Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin.

Authors:  Shu-ichi Okamoto; Mahmoud A Pouladi; Maria Talantova; Dongdong Yao; Peng Xia; Dagmar E Ehrnhoefer; Rameez Zaidi; Arjay Clemente; Marcus Kaul; Rona K Graham; Dongxian Zhang; H-S Vincent Chen; Gary Tong; Michael R Hayden; Stuart A Lipton
Journal:  Nat Med       Date:  2009-11-15       Impact factor: 53.440
View more
  3 in total

Review 1.  The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.

Authors:  Gabriele Sani; Giulia Serra; Giorgio D Kotzalidis; Silvia Romano; Stefano M Tamorri; Giovanni Manfredi; Matteo Caloro; C Ludovica Telesforo; Saverio S Caltagirone; Isabella Panaccione; Alessio Simonetti; Francesca Demontis; Gino Serra; Paolo Girardi
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

Review 2.  Memantine: New prospective in bipolar disorder treatment.

Authors:  Giulia Serra; Francesca Demontis; Francesca Serra; Lavinia De Chiara; Andrea Spoto; Paolo Girardi; Giulio Vidotto; Gino Serra
Journal:  World J Psychiatry       Date:  2014-12-22

3.  Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial.

Authors:  Jayashri Kulkarni; Natalie Thomas; Abdul-Rahman Hudaib; Emorfia Gavrilidis; Jasmin Grigg; Raelene Tan; Jacinta Cheng; Amelia Arnold; Caroline Gurvich
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.